Shopping Cart
Remove All
Your shopping cart is currently empty
Etofenamate
Copy Product Info
🥰Excellent
Catalog No. T2553Cas No. 30544-47-9
Etofenamate is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of joint and muscular pain.
Etofenamate
Copy Product Info🥰Excellent
Purity: 99.97%
Catalog No. T2553Cas No. 30544-47-9
Etofenamate is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of joint and muscular pain.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $36 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $50 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.97%
Contact us for more batch information
Product Introduction
Etofenamate AI Summary
Etofenamate exhibits a range of bioactivities across various biological assays. It functions as a potent modulator of Lamin A splicing with a potency of 50.1 nM and acts as an inhibitor for several enzymes such as Cruzain (15848.9 nM), Cytochrome P450 2C19 (10000.0 nM), and Cytochrome P450 2C9 (12589.3 nM). It also demonstrates activity in modulating lipid storage and has notable potencies in Cytochrome p450-cyp2c9 (12589.25 nM), p450-cyp2c19 (10000.0 nM), and p450-cyp1a2 (316.23 nM) assays. Furthermore, Etofenamate shows inhibitory activity against USP1/UAF1 (31622.8 nM) and human tyrosyl-DNA phosphodiesterase 1 (TDP1).
In the context of antiviral activities, Etofenamate inhibits SARS-CoV-2 induced cytotoxicity in Vero E6 and Caco-2 cells, though with modest efficacy shown by slight decreases in cell viability and low activity hit scores. It demonstrates antiviral activity against the SARS-CoV-2 3CL-Pro protease with an inhibition of 9.348% at a 20 µM concentration. Additionally, it shows inhibition percentages on HDAC6 enzyme, with a higher inhibition rate of 46.44% using a commercial peptide substrate compared to 2.16% with a custom peptide substrate.
Overall, Etofenamate exhibits diverse bioactivities including enzyme inhibition, modulation of cellular functions, and antiviral properties against multiple targets and pathogens..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Etofenamate is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of joint and muscular pain. |
| Molecular Weight | 369.33 |
| Formula | C18H18F3NO4 |
| Cas No. | 30544-47-9 |
| Smiles | N(C1=C(C(OCCOCCO)=O)C=CC=C1)C2=CC(C(F)(F)F)=CC=C2 |
| Relative Density. | 1.2866 g/cm3 (Estimated) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 250 mg/mL (676.9 mM)  DMSO: 5.2 mg/mL (14.08 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.71 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
Ethanol
| |||||||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Etofenamate | purchase Etofenamate | Etofenamate cost | order Etofenamate | Etofenamate chemical structure | Etofenamate formula | Etofenamate molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.